Episode Details

Summary

In this episode of Melanoma Matters, Sapna Patel and James Larkin discuss the IMMUNED study, a randomized phase 2 trial for resected stage 4 melanoma with no evidence of disease (NED). They explore the study design, efficacy results, and subgroups analysis. They also discuss the use of checkpoint inhibitors in the adjuvant setting and the management of oligometastatic disease. The key takeaway is that anti-PD-1 monotherapy is likely under treatment for stage 4 NED, but the approach may vary depending on individual patient factors and reimbursement limitations.

Keywords

Melanoma, IMMUNED study, stage 4 NED, checkpoint inhibitors, adjuvant therapy, oligometastatic disease

Takeaways

• Anti-PD-1 monotherapy is likely under treatment for stage 4 NED.
• The IMMUNED study showed a significant benefit in recurrence-free survival with ipilimumab plus nivolumab compared to placebo.
• BRAF mutation status may influence the response to immunotherapy in stage 4 NED.
• The management of oligometastatic disease requires individualized approaches and consideration of factors such as tempo, toxicity, and patient preferences.
• Reimbursement limitations may impact treatment decisions in the adjuvant setting.

Sound Bites

"Anti-PD-1 monotherapy is probably under treatment for stage 4 NED."

"The BRAF mutation status is consistent with what we saw in Checkmate 67."

"The management of oligometastatic disease requires individualized approaches."

Chapters

00:00 Introduction and Childhood Jobs

04:03 Overview of the IMMUNED Study

07:51 Efficacy and Forest Plots

10:47 Utilizing the IMMUNED Study in the Clinic

14:29 Subgroup Analysis and BRAF Status

21:11 Treatment Algorithms for Stage IV NED

26:46 Managing Oligometastatic Disease

30:54 No Easy Answers and Controversial Questions

34:10 Personalized Treatment and Reimbursement Limitations